Search results
Author(s):
Brian Lindman
Added:
2 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Arditya Damarkusuma
,
Paula Mota
,
Billal Patel
,
et al
Added:
1 year ago
Author(s):
Luca Paolucci
,
Asad Shabbir
,
Marco Lombardi
,
et al
Added:
5 months ago
Author(s):
Arditya Damarkusuma
Added:
1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper…
View more
Author(s):
Jacob Thomsen Lønborg
Added:
3 weeks ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent…
View more
Author(s):
Hyo-Soo Kim
Added:
2 months ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
Author(s):
David Power
Added:
4 months ago
Outcomes investigating the Absorb bioresorbable vascular scaffold (BVS) in patients undergoing percutaneous coronary intervention showed more adverse ischaemic events through 5 years compared with cobalt-chromium everolimus-eluting stents. However, the period of excess risk ended at 3 years.In this short interview, Dr David Power (Mount Sinai Hospital, New York, US) discusses the final report…
View more
Author(s):
Viktor Sasi
,
Gyula Szántó
,
Alexandru Achim
,
et al
Added:
1 year ago
AF, Stent and Anticoagulant
Author(s):
Balen Abdulrahman
,
Richard J Jabbour
,
Nick Curzen
Added:
2 years ago
Article
Author(s):
Marc Dweck
Added:
7 months ago
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143;…
View more